agreement of termination of the contract ( translation ) party a : harbin tianmu pharmaceutical co., ltd. inc. ( tongli ) party b : tonghua yisheng pharmaceutical co., ltd. inc. ( yisheng ) due to the manufacture issues of the yisheng resulting in being unable to conduct clinical trials of the new product, the tongli decided to terminate the purchase contract of the product. according to the negotiation, the tongli and the yisheng mutually agreed to discontinue the contract with the following agreements : 1. according to the current issues of the yisheng ’ s product, the tongli cannot conduct the late stage clinical trials of “ nafaruilin ”, the product that the tongli purchased from yisheng. therefore, the tongli asked the yisheng to terminate all of the clinical trials of the product before june 15th, 2012. 1. according to the current issues of the yisheng ’ s product, the tongli cannot conduct the late stage clinical trials of “ nafaruilin ”, the product that the tongli purchased from yisheng. therefore, the tongli asked the yisheng to terminate all of the clinical trials of the product before june 15th, 2012. 1. 2. the yisheng will repay 22 million renminbi yuan ( ¥22, 000, 000 ) of the advance payment to the tongli. the due dates and amounts of the repayments are : 2. the yisheng will repay 22 million renminbi yuan ( ¥22, 000, 000 ) of the advance payment to the tongli. the due dates and amounts of the repayments are : 2. 1 ) five million ( ¥5, 000, 000 ) renminbi yuan, before august 30th, 2012. 1 ) five million ( ¥5, 000, 000 ) renminbi yuan, before august 30th, 2012. 1 ) 2 ) six million ( ¥6, 000, 000 ) renminbi yuan, before november 30th, 2012. 2 ) six million ( ¥6, 000, 000 ) renminbi yuan, before november 30th, 2012. 2 ) 3 ) eight million ( ¥8, 000, 000 ) renminbi yuan, before february 28th, 2013. 3 ) eight million ( ¥8, 000, 000 ) renminbi yuan, before february 28th, 2013. 3 ) 4 ) three million ( ¥3, 000,